TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01802437
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
Study: NCT03813186
Drug: ASTX727 + Day 2 Food
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
Study: NCT01088243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Study: NCT03141983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
Study: NCT00239564
Drug: IPX054 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX054 containing 25 mg carbidopa and 100 mg levodopa
Study: NCT00239564
Drug: IPX054 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
Study: NCT00239564
Drug: IPX054 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
Study: NCT03590600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo: powder and solvent for oral suspension
Study: NCT02526875
Drug: Telminuvo®Tab. 40/2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study: NCT01575275
Drug: aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03839875
Drug: Gynomax® XL Vaginal Ovule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tioconazole, tinidazole, lidocaine
Study: NCT03738800
Drug: CD5789 Cream 200 µg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
Study: NCT03738800
Drug: CD5789 Cream Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
Study: NCT02072330
Drug: TAK-536CCB + Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
Study: NCT00777361
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iv single dose, 4-hour infusion of 25 mg
Study: NCT01674309
Drug: FOLFORINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTRAVENOUS administration
Study: NCT01271998
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, oral, once daily for 3 days.
Study: NCT02072330
Drug: TAK-536CCB + Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
Study: NCT00777361
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution single dose of 50 mg
Study: NCT00690079
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
Study: NCT00690079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral admin. of doses at 11 days through a 12 days period.
Study: NCT00147615
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02481011
Drug: antithrombotic drugs
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01472757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered via a new dry powder inhaler
Study: NCT02956057
Drug: Polyethylene glycol / Ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00565916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
Study: NCT03685396
Drug: hemostatic agents with oxidized and regenerated cellulosa
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
Study: NCT04508179
Drug: 7HP349 Single Ascending Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
Study: NCT04508179
Drug: Placebo Single Ascending Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Placebo Capsules, Single Ascending Dose (SAD)
Study: NCT04508179
Drug: Placebo Multiple Ascending Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
Study: NCT04508179
Drug: 7HP349 Food Effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part C: 7HP349 Capsules, Food Effect
Study: NCT04489381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets administered orally twice daily with food for 5 days
Study: NCT01494155
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
Study: NCT00215540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
Study: NCT00760370
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg intravenous (iv), one treatment
Study: NCT03831984
Drug: 0,09% Bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
Study: NCT02696564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule per day for two weeks, followed by two capsules per day for 46 weeks
Study: NCT03857568
Drug: SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug will be dosed repeatedly
Study: NCT03857568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dosed repeatedly
Study: NCT00032890
Drug: glucosamine
Normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00032890
Drug: glucosamine and chondroitin sulfate combined
Normalized name: chondroitin sulfates / glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00032890
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04605432
Drug: PEG-FFI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher.
Study: NCT04605432
Drug: PEG-nonFFI
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse.
Study: NCT01313494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT00111371
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02479971
Drug: Clindamycin-gentamicin irrigation
Normalized name: gentamicin Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
Study: NCT02604550
Drug: Percocet 7.5/325
Normalized name: Percocet 7.5/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percocet 7.5/325 will taken as needed up to every four hours.
Study: NCT01270386
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo p.o. once daily
Study: NCT01931241
Drug: AHRO-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
Study: NCT04447534
Drug: zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc tablets
Study: NCT02938949
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00570349
Drug: Nitric Oxide for Inhalation
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
Study: NCT00570349
Drug: Nitric Oxide for Inhalation
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
Study: NCT03830203
Drug: BAT1806
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg
Study: NCT03707639
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT01368107
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
Study: NCT01021488
Drug: Rosuvastatin 20mg/d for 14days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
Study: NCT01732471
Drug: Kuvan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
Study: NCT03347344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg will be administered (per os) twice a day
Study: NCT01870804
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01870674
Drug: YH12852
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01870674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01135069
Drug: Tretinoin microsphere 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of acne vulgaris
Study: NCT01135069
Drug: Brand Retin-A Micro tretinoin microsphere gel 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of acne vulgaris
Study: NCT01681316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study: NCT02468128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
Study: NCT01422135
Drug: AG200-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
Study: NCT00574249
Drug: placebo (vehicle ointment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Study: NCT00805090
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 37.5 mg
Study: NCT04944303
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal doseage of normal saline was injected to reverse the NMB.
Study: NCT03258424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTI-428 or placebo will be given QD for 14 days.
Study: NCT00232596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT01953432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo daily dosing
Study: NCT02648477
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01399606
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,10,20,or 40 mg per day, in a once daily scheme
Study: NCT02674399
Drug: JointStem
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02674399
Drug: Synvisc-One
Normalized name: Synvisc-One 48mg/6ml Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02089529
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen/Ibumetin with no information, positive information and neutral information
Study: NCT02089529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with no information, positive information and neutral information
Study: NCT02544191
Drug: GnRHa/ hCG/ hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
Study: NCT03479892
Drug: NNC0194-0499
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Study: NCT03479892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once weekly injections of NNC0194-0499 matched placebo.
Study: NCT02978859
Drug: MGCD516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
Study: NCT00955981
Drug: RDEA594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uricosuric agent for the treatment of gout
Study: NCT00955981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02079636
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02437032
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation with 150-300 UI recombinant FSH
Study: NCT02437032
Drug: Urinary FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation with 150-300 UI urinary FSH
Study: NCT02437032
Drug: hMG
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation with 150-300 UI hMG
Study: NCT00689559
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 capsules qd, oral, 22 days
Study: NCT00689559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo qd, 12 days
Study: NCT02099188
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2/day - Powder for solution for infusion
Study: NCT01275911
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
Study: NCT01929161
Drug: Placebo (for oxytocin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal spray manufactured to mimic oxytocin nasal spray
Study: NCT03762343
Drug: ultrasound guided Greater occipital nerve block
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
Study: NCT04364113
Drug: Medications needed to maintain usual blood pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
Study: NCT01758198
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04806659
Drug: SH1573 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Study: NCT02046083
Drug: arachid
Normalized name: arachidate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01524783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were treated with two tablets of matching placebo once daily orally taken.
Study: NCT03035305
Drug: Seasonal malaria chemoprevention
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine
Study: NCT00733083
Drug: NaCl 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection one injection in the beginning of anesthesia
Study: NCT03663764
Drug: Thymosin a1
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
Study: NCT00948506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical placebo
Study: NCT03663764
Drug: concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
Study: NCT00356252
Drug: mixed carotenoids
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04627532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will recieve placebo
Study: NCT00477607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
Study: NCT01173055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally twice daily in tablet form at different times during the course of the study.
Study: NCT01829178
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 420 mg in 3 divided dose plus standard chemotherapy
Study: NCT01829178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets: 420 mg in 3 divided dose
Study: NCT01829178
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
Study: NCT03467763
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00003910
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
Study: NCT00003910
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
Study: NCT00704301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 times a day
Study: NCT03844243
Drug: Isotonic-saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT01903785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no